Novel Oral Anticoagulants at 10: An Assessment of their Safety and Contemporary Use in Atrial Fibrillation

Published: 04 March 2021

  • Views:

    Views Icon 29584
  • Likes:

    Heart Icon 7
  • episode_image
    Now Playing
    Part 3 | Session 1 of 1
    Jan Steffel
    Jan Steffel
    Up Next
  • episode_image
    Part 1 | Session 1 Jan Steffel John Eikelboom, Ken Okumura, Jan Steffel, Stefan H Hohnloser

Overview

In this virtual roundtable, our expert panel reflect on the clinical trials and real world data supporting the use of NOACs in atrial fibrillation – almost ten years since they entered the clinic.

Moderated by Prof John Eikelboom, the panel offer their analyses via a series of presentations and discussions covering a range of topics, with a special focus on their use in Japan.

This activity has been supported via an educational grant from Boehringer Ingelheim

Learning Objectives

  • Identify which individuals with atrial fibrillation should be initiated on NOAC therapy without delay
  • Interpret safety and cardiovascular data from RCTs in the context of real-world experience
  • Select appropriate treatment strategies with NOACs in atrial fibrillation patients in need of further ablation or intervention
  • Review the reversal options open to individuals experiencing a bleeding event whilst on treatment with a NOAC

Target Audience

  • Cardiologists
  • Interventional Cardiologists

More from this programme

Part 1

When to Initiate a NOAC and Patient Suitability (data presentation)

An overview of current guidelines

Part 2

Overview of Safety and Cardiovascular Data

a. Safety and cardiovascular data from RCTs b. Real-world and meta-analyses

Part 3

Dealing with Complications:

Major bleeding events and reversal

Part 4

Discussion on Safety Rates and Patient Suitability (Panel Discussion Session)

Panel recommendations of NOAC choice according to different patient populations

Part 5

NOAC Use with Ablation and Intervention

a. Guideline recommendations and current trends b. Use of NOACs with ablation in Japan: clinical data

Part 6

Discussion on the Current Use of NOACs in Japan

a. Use in elderly/very old pts b. Under-dosing of NOACs c. Current unmet needs

Faculty Biographies

Jan Steffel

Jan Steffel

Senior Consultant in Electrophysiology and Devices

Professor Jan Steffel is a Cardiologist and Senior Consultant in Electrophysiology and Devices at the Hirslanden Clinic in Zurich and Professor of Cardiology at the University of Zurich.

He has over 150 publications in international and national journals and is board-certified in Internal Medicine and Cardiology.  He was Associate Editor for the European Heart Journal from 2012 and became Deputy Editor in 2017. He is a member of the Foederatio Medicorum Helveticorum (FMH), Swiss Society for General Internal Medicine (SGAIM), Swiss Society for Cardiology (SGK) and European Society of Cardiology (ESC).

Since 2012, Prof Steffel has been involved with the

View full profile